PRF Technologies Ltd (PRFX) Stock Analysis

AI analysis of PRF Technologies Ltd (PRFX)

Hold

PainReform Ltd (PRFX) is not a good buy right now due to significant financial losses and high volatility. The current price is $0.85, and the stock has a 1-year change of -81.86%, indicating a substantial decline over the past year. While the recent 5-day change of +16.01% shows some short-term recovery, the overall trend and financial performance suggest caution. The RSI is at 73.416, indicating that the stock is overbought, which could lead to a price correction. Additionally, the forward P/E ratio is 0, reflecting uncertainty about future earnings, and the gross margin has been negative, with figures like -4776.47% in Q4 2025. The main risk is the high volatility and the potential for further declines, as evidenced by the 52-week low of $0.64.

Valuation Metrics

The current forward P/E ratio for PRF Technologies Ltd (PRFX) is 0.00, compared to its 5-year average forward P/E of -1.93.

Forward P/E

Fair

5Y Average P/E

-1.93

Current P/E

0.00

Overvalued

0.72

Undervalued

-4.59

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Strongly Undervalued

5Y Average P/S

0.00

Current P/S

0.00

Overvalued

0.00

Undervalued

0.00

Alphio AI Price Scenarios for PRFX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PRFX

$1.94

Scenario price

B

Base

Base · 50%PRFX

$1.75

Scenario price

B

Bear

Bear · 25%PRFX

$1.65

Scenario price

PRFX FAQ — answered by Alphio AI

PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

PainReform Ltd (PRFX) is not a good buy right now due to significant financial losses and high volatility. The current price is $0.85, and the stock has a 1-year change of -81.86%, indicating a substantial decline over the past year. While the recent 5-day change of +16.01% shows some short-term recovery, the overall trend and financial performance suggest caution. The RSI is at 73.416, indicating that the stock is overbought, which could lead to a price correction. Additionally, the forward P/E ratio is 0, reflecting uncertainty about future earnings, and the gross margin has been negative, with figures like -4776.47% in Q4 2025. The main risk is the high volatility and the potential for further declines, as evidenced by the 52-week low of $0.64.